4baseCare Bags ₹38 Cr To Close Series B Round At ₹128 Cr

Why It Matters

The capital accelerates 4baseCare’s global lab rollout and AI platform, positioning it to capture a growing share of the $37 billion Indian healthtech market by 2030.

Key Takeaways

• 4baseCare’s Series B totals $13 M, led by growX Ventures
• Funds target labs in Asia, Middle East, Latin America, Central Asia
• OncoTwin AI platform will receive expanded development resources
• Series B follows a $10.8 M raise six months earlier
• Healthtech funding surge reflects AI‑driven precision medicine demand

Pulse Analysis

4baseCare’s latest financing round marks a pivotal moment for Indian healthtech firms seeking global scale. By closing its Series B at ₹128 crore ($13 million), the Bengaluru‑based startup joins a wave of capital inflows that include StrainX Bioworks’ $13 million raise and Practo co‑founder Shashank ND’s $5 million seed. Investors are betting on the convergence of genomics and artificial intelligence to transform oncology care, a sector traditionally hampered by fragmented data and limited diagnostic reach.

The newly secured ₹38 crore ($4 million) will primarily fund the expansion of 4baseCare’s genomics laboratory network across emerging markets such as the Middle East, Southeast Asia, Latin America and Central Asia. This geographic diversification aims to tap underserved patient populations while building a robust data repository that feeds OncoTwin, the company’s AI‑powered precision‑oncology platform. OncoTwin leverages bioinformatics to deliver clinically actionable insights, helping oncologists tailor treatments based on a patient’s unique genetic and lifestyle profile. Scaling both the lab footprint and AI capabilities positions 4baseCare to become a critical data hub in the global fight against cancer.

The broader healthtech ecosystem in India is experiencing a renaissance, driven by AI adoption and a shift toward preventive, longevity‑focused solutions. Inc42 projects the Indian healthtech market to reach $37 billion by 2030, attracting both domestic and foreign capital. 4baseCare’s successful fundraising underscores confidence that integrated genomics and AI can deliver measurable clinical outcomes, thereby unlocking new revenue streams and reinforcing India’s reputation as a hub for innovative, export‑ready health technologies.